In AD, N-terminal to mid-domain tau fragments, both phosphorylated and non-phosphorylated variants, are released into the cerebrospinal fluid (CSF) early in disease progression, which has enabled the development of biomarkers for disease prognosis, diagnosis, and staging [19, 32, 57, 67, 110, 111]. Here, MAPT is linked to Alzheimer disease.